DICE News and Press, DICE Therapeutics Inc. From 05/13/22

The following slide deck was published by DICE Therapeutics, Inc. in conjunction with this event. For further details see: DICE Therapeutics (DICE) Investor Presentation - Slideshow

DICE Therapeutics press release (NASDAQ:DICE): Q1 GAAP EPS of -$0.50. Cash, cash equivalents and marketable securities totaled $303.2 million at March 31, 2022. The Company expects its current cash position to fund operations through mid-2024 and expected key clinical milestones. For furthe...

Topline proof-of-concept data from Phase 1 clinical trial of oral IL-17 antagonist DC-806 in healthy volunteers and psoriasis patients expected in mid-2022 Current cash provides runway through mid-2024 and multiple expected key clinical milestones SOUTH SAN FRANCISCO, Calif., Ma...

SOUTH SAN FRANCISCO, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therape...

DICE Therapeutics Inc. (NASDAQ:DICE) traded at a new 52-week high today of $40.50. So far today approximately 1 million shares have been exchanged, as compared to an average 30-day volume of 331,000 shares. DICE Therapeutics Inc is a biopharmaceutical company leveraging proprietary techn...

DICE Therapeutics press release (NASDAQ:DICE): Q4 GAAP EPS of -$0.44 beats by $0.19. Cash, cash equivalents and marketable securities totaled $319.3 million at December 31, 2021. The Company expects its current cash position to fund operations through mid-2024 and expected key clinical milest...

On track to deliver topline proof-of-concept data from Phase 1 clinical trial of oral IL-17 antagonist DC-806 in healthy volunteers and psoriasis patients in mid-2022 Named development candidate DC-853 from the novel scaffold program 1 series of oral IL-17 franchise Current cash p...

SOUTH SAN FRANCISCO, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therap...

Gainers: uCloudlink Group  (NASDAQ:UCL) +15%. Quantum-Si Incorporated QSI +10%. Micron Technology  MU +7%. Braze BRZE +6%. JAKKS Pacific (NASDAQ:JAKK) +6%. Losers: CytomX Therapeutics CTMX -29%. DBV Technologies  (NASDAQ:DBVT) -13%. Sigilon Therape...

SOUTH SAN FRANCISCO, Calif., Nov. 16, 2021 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therap...